MX2020005658A - Profarmacos de union a albumina de derivados de auristatina e. - Google Patents

Profarmacos de union a albumina de derivados de auristatina e.

Info

Publication number
MX2020005658A
MX2020005658A MX2020005658A MX2020005658A MX2020005658A MX 2020005658 A MX2020005658 A MX 2020005658A MX 2020005658 A MX2020005658 A MX 2020005658A MX 2020005658 A MX2020005658 A MX 2020005658A MX 2020005658 A MX2020005658 A MX 2020005658A
Authority
MX
Mexico
Prior art keywords
albumin
auristatin derivatives
binding prodrugs
prodrugs
binding
Prior art date
Application number
MX2020005658A
Other languages
English (en)
Inventor
Felix Kratz
Ajaj Khalid Abu
Stephan David Koester
Friederike I Nollmann
Fernandez Javier Garcia
Anna Warnecke
Lara Pes
Heidi-Kristin Walter
Johannes Pall Magnusson
Serghei Chercheja
Galan Patricia Perez
Federico Medda
Steffen Josef Daum
Original Assignee
Centurion Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centurion Biopharma Corp filed Critical Centurion Biopharma Corp
Publication of MX2020005658A publication Critical patent/MX2020005658A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación proporciona profármacos de unión a albúmina de derivados de auristatina E y sus usos.
MX2020005658A 2017-11-30 2018-11-30 Profarmacos de union a albumina de derivados de auristatina e. MX2020005658A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762592721P 2017-11-30 2017-11-30
PCT/US2018/063376 WO2019108974A1 (en) 2017-11-30 2018-11-30 Albumin-binding prodrugs of auristatin e derivatives

Publications (1)

Publication Number Publication Date
MX2020005658A true MX2020005658A (es) 2020-11-11

Family

ID=64744961

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005658A MX2020005658A (es) 2017-11-30 2018-11-30 Profarmacos de union a albumina de derivados de auristatina e.

Country Status (15)

Country Link
US (1) US11377473B2 (es)
EP (2) EP4344747A3 (es)
JP (1) JP7359449B2 (es)
KR (1) KR20200118408A (es)
CN (2) CN118852324A (es)
AU (1) AU2018375787B2 (es)
BR (1) BR112020009836A2 (es)
DK (1) DK3717503T3 (es)
ES (1) ES2970618T3 (es)
IL (1) IL274919B2 (es)
MX (1) MX2020005658A (es)
NZ (1) NZ764948A (es)
PT (1) PT3717503T (es)
WO (1) WO2019108974A1 (es)
ZA (1) ZA202002951B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3954394A1 (en) 2015-06-19 2022-02-16 Centurion BioPharma Corporation Delivery systems for controlled drug release
CN111712263B (zh) 2017-11-30 2024-12-17 拉德克斯公司 基于美登木素生物碱的药物递送系统
CN113321698B (zh) * 2020-02-28 2022-08-23 国家纳米科学中心 一种单甲基澳瑞他汀e前药及其制备方法和应用
CA3183613A1 (en) * 2020-05-19 2021-11-25 Les Laboratoires Servier Para-amino-benzyl linkers, process for their preparation and their use in conjugates
CN115969986A (zh) * 2022-12-30 2023-04-18 上海药明生物技术有限公司 羟丙基β环糊精稳定MMAE类抗体药物偶联物制剂的应用
WO2024230301A1 (zh) * 2023-05-09 2024-11-14 诺灵生物医药科技(北京)有限公司 一种抗体偶联药物及其用途
CN116813569B (zh) * 2023-07-10 2024-07-02 衡阳市中心医院 一种抗癌药中间体的制备方法和抗癌药的制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4125704A (en) 1977-09-14 1978-11-14 Sri International Phenyl-substituted rubidazone analogs
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US4966999A (en) 1988-06-07 1990-10-30 Cytogen Corporation Radiohalogenated compounds for site specific labeling
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6884869B2 (en) * 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
JP5448299B2 (ja) 2003-12-04 2014-03-19 アルバニー モレキュラー リサーチ， インコーポレイテッド ビンカ誘導体
SI2032606T1 (sl) * 2006-05-30 2014-02-28 Genentech, Inc. Protitelesa in imunokonjugati in njihove uporabe
JP5634862B2 (ja) 2007-05-16 2014-12-03 カーテーベー トゥモーアフォルシュングス ゲゼルシャフト ミット ベシュレンクテル ハフツング 低粘度アントラサイクリン製剤
EP2289558A1 (en) 2009-08-25 2011-03-02 KTB Tumorforschungsgesellschaft mbH Bisphosphonate-prodrugs
EP2630971B8 (en) 2012-02-21 2017-12-13 Vergell Medical S.A. Combinations of albumin-based drug delivery systems
US20140221429A1 (en) 2013-02-04 2014-08-07 Saud Ibrahim Al-Resayes Heterocyclic schiff's bases as novel and new antiglycation agents
FR3005051A1 (fr) * 2013-04-25 2014-10-31 Pf Medicament Derives de la dolastatine 10 et d'auristatines
JP6908964B2 (ja) * 2013-10-18 2021-07-28 ピーエスエムエー ディベロップメント カンパニー，エルエルシー Ｐｓｍａリガンドコンジュゲートによる併用療法
FR3017298B1 (fr) 2014-02-07 2016-03-04 Centre Nat Rech Scient Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires
WO2016055907A1 (en) * 2014-10-10 2016-04-14 Pfizer Inc. Synergistic auristatin combinations
EP3307164B1 (en) 2015-06-15 2021-05-12 Abbott Diabetes Care Inc. Stabilized lactate responsive enzymes, electrodes and sensors, and methods for making and using the same
EP3954394A1 (en) * 2015-06-19 2022-02-16 Centurion BioPharma Corporation Delivery systems for controlled drug release
CN111712263B (zh) 2017-11-30 2024-12-17 拉德克斯公司 基于美登木素生物碱的药物递送系统
US11632502B2 (en) 2021-09-10 2023-04-18 Pixart Imaging Inc. Optical sensor cancelling image flicker

Also Published As

Publication number Publication date
PT3717503T (pt) 2024-01-16
EP4344747A2 (en) 2024-04-03
AU2018375787B2 (en) 2023-02-23
US20200385421A1 (en) 2020-12-10
CN111712511B (zh) 2024-07-16
EP3717503B1 (en) 2023-11-08
IL274919B2 (en) 2025-05-01
KR20200118408A (ko) 2020-10-15
DK3717503T3 (da) 2024-01-22
CA3083983A1 (en) 2019-06-06
BR112020009836A2 (pt) 2020-10-13
JP2021505541A (ja) 2021-02-18
WO2019108974A1 (en) 2019-06-06
CN118852324A (zh) 2024-10-29
IL274919B1 (en) 2025-01-01
RU2020121451A (ru) 2021-12-30
US11377473B2 (en) 2022-07-05
JP7359449B2 (ja) 2023-10-11
EP4344747A3 (en) 2024-07-03
CN111712511A (zh) 2020-09-25
ES2970618T3 (es) 2024-05-29
AU2018375787A1 (en) 2020-06-18
IL274919A (en) 2020-07-30
NZ764948A (en) 2024-08-30
ZA202002951B (en) 2023-10-25
EP3717503A1 (en) 2020-10-07

Similar Documents

Publication Publication Date Title
CL2019000992A1 (es) Conjugados de pirrolobenzodiazepina.
SV2018005683A (es) Formulaciones subcutaneas de anticuerpos anti-cd38 y sus usos
CY1124131T1 (el) Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου
CL2019002824A1 (es) Anticuerpos anti-lag3.
MX2018009938A (es) Profarmacos de hormona paratiroidea (pth).
CO2020012347A2 (es) Anticuerpos anti-hla-g y usos de los mismos.
CL2018000947S1 (es) Automóvil
CL2019003168A1 (es) Mejoras farmacocinéticas de quelatos bifuncionales y usos de los mismos.
TWD193949S (zh) 前保險桿之蒙皮
BR112018008960A2 (pt) estrutura de relatório de formação de feixe
MX373323B (es) Procesos de siembra en serie y usos de los mismos.
ZA202002951B (en) Albumin-binding prodrugs of auristatin e derivatives
JOP20170120A1 (ar) مشتقات اندول حلقية ضخمة
BR112017013029A2 (pt) síntese comercialmente viável de cantaridina e de-rivados de cantaridina bioativos
AR109376A1 (es) FORMULACIONES DE g-HIDROXIBUTIRATO DE LIBERACIÓN MODIFICADA
CL2018000791S1 (es) Automóvil
ECSDI17031122S (es) Recipiente contenedor [i] [c]
ECSDI18002267S (es) Mandolina
ECSDI17024111S (es) Recipiente
CL2017000645A1 (es) Síntesis de ent-progesterona e intermediarios de la misma
EP3683967A4 (en) SIGNAL SOURCE
JOP20200056A1 (ar) تركيب غلاية
CL2019000806S1 (es) Cabezal de cepillo de dientes.
CL2019000807S1 (es) Cabezal de cepillo de dientes.
CL2019000808S1 (es) Cabezal de cepillo de dientes.